Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331643 · ClinicalTrials.gov registry record · Phase 2
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Recurrent Childhood Rhabdomyosarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00331643: Completed Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Recurrent Childhood Rhabdomyosarcoma, sponsored by National Cancer Institute (NCI).
NCT00331643 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Recurrent Childhood Rhabdomyosarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 120 participants, above the 78-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (54% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00331643, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Recurrent Childhood Rhabdomyosarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Primary Outcome
Estimated using the product-limit method of Kaplan and Meier.
Conditions Studied
Interventions
- DRUG ixabepilone
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00331643 record still lists
NCT00331643 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 78-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (54% higher).
The record links to 10 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which ixabepilone is the first listed.
NCT00331643 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00331643 about?
NCT00331643 is a clinical study titled "Ixabepilone in Treating Young Patients With Refractory Solid Tumors". This phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
What is the current status of trial NCT00331643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2006-04. Estimated completion is 2009-06.
What conditions does trial NCT00331643 study?
This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Adult Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma.
What interventions are being tested in trial NCT00331643?
The interventions under investigation include: ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00331643?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00331643 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00331643's enrollment target sits among peer trials
120 4th of 11 higher than 8 of 11 other Recurrent Adult Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Adult Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
COMPLETED · Phase 2
-
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
COMPLETED · Phase 2
-
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia